|
KMID : 0338420140290060807
|
|
The Korean Journal of Internal Medicine
2014 Volume.29 No. 6 p.807 ~ p.813
|
|
|
Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor use
|
|
Lim Mie-Jin
Kwon Seong-Ryul
Joo Ko-Woon
Son Min-Jung
Park Shin-Goo
Park Won
|
|
|
Abstract
|
|
|
Background/Aims: Our aim was to assess whether short-term treatment with soluble tumor necrosis factor (TNF) receptor affects circulating markers of bone metabolism in rheumatoid arthritis (RA) patients.
Methods: Thirty-three active RA patients, treated with oral disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids for > 6 months, were administered etanercept for 12 weeks. Serum levels of bone metabolism markers were compared among patients treated with DMARDs at baseline and after etanercept treatment, normal controls and naive RA patients not previously treated with DMARDs (both age- and gender-matched).
Results: Bone-specific alkaline phosphatase (BSALP) and serum c-telopeptide (CTX)-1 levels were lower in RA patients treated with DMARDs than in DMARDnaive RA patients. After 12 weeks of etanercept treatment, serum CTX-1 and sclerostin levels increased. In patients whose DAS28 improved, the sclerostin level increased from 1.67 ± 2.12 pg/mL at baseline to 2.51 ± 3.03 pg/mL, which was statistically significant (p = 0.021). Increases in sclerostin levels after etanercept treatment were positively correlated with those of serum CTX-1 (r = 0.775), as were those of BSALP (r = 0.755).
Conclusions: RA patients treated with DMARDs showed depressed bone metabolism compared to naive RA patients. Increases in serum CTX-1 and sclerostin levels after short-term etanercept treatment suggest reconstitution of bone metabolism homeostasis.
|
|
|
KEYWORD
|
|
|
Arthritis, rheumatoid, Bone remodeling, TNFR-Fc fusion protein
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|